KYMERA THERAPEUTICS, INC. Financing Cash Flow
KYMERA THERAPEUTICS, INC. (KYMR) reported Financing Cash Flow of $33.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $14.42M, a 94.13% decline year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $18.77M, a 7174.81% increase year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $705.22M, a 25405.21% increase year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $39.51M, a 84.25% decline year-over-year.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2025 was $990.71M, a 62.72% increase from fiscal 2024.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2024 was $608.85M, a 14424.12% increase from fiscal 2023.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2023 was $4.19M, a 97.26% decline from fiscal 2022.
- KYMERA THERAPEUTICS, INC. net cash provided by (used in) financing activities for fiscal 2022 was $153.00M, a 38.87% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $33.19M 10-Q · filed 2026-08-05 | $738.41M derived: sum of 3 quarters · filed 2026-08-05 | $777.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $18.77M 10-Q · filed 2026-04-30 | $723.99M derived: sum of 2 quarters · filed 2026-04-30 | $763.50M derived: sum of 3 quarters · filed 2026-04-30 | $1.01B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $705.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $744.73M derived: sum of 2 quarters · filed 2026-02-26 | $990.46M derived: sum of 3 quarters · filed 2026-08-05 | $990.71M 10-K · filed 2026-02-26 |
| 2025-09-30 | $39.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $285.24M derived: sum of 2 quarters · filed 2026-08-05 | $285.49M 10-Q · filed 2025-11-04 | $288.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $245.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $245.98M 10-Q · filed 2026-08-05 | $248.75M derived: sum of 3 quarters · filed 2026-08-05 | $499.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $258.00K 10-Q · filed 2026-04-30 | $3.02M derived: sum of 2 quarters · filed 2026-04-30 | $253.94M derived: sum of 3 quarters · filed 2026-04-30 | $255.35M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $253.68M derived: sum of 2 quarters · filed 2026-02-26 | $255.09M derived: sum of 3 quarters · filed 2026-02-26 | $608.85M 10-K · filed 2026-02-26 |
| 2024-09-30 | $250.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $252.33M derived: sum of 2 quarters · filed 2025-11-04 | $606.09M 10-Q · filed 2025-11-04 | $608.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $355.17M 10-Q · filed 2025-08-11 | $357.10M derived: sum of 3 quarters · filed 2026-02-26 | $356.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $353.76M 10-Q · filed 2025-05-09 | $355.69M derived: sum of 2 quarters · filed 2026-02-26 | $355.48M derived: sum of 3 quarters · filed 2026-02-26 | $356.79M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.73M derived: sum of 2 quarters · filed 2026-02-26 | $3.03M derived: sum of 3 quarters · filed 2026-02-26 | $4.19M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$206.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $1.10M derived: sum of 2 quarters · filed 2024-10-31 | $2.26M 10-Q · filed 2024-10-31 | $4.21M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.46M 10-Q · filed 2024-08-07 | $4.42M derived: sum of 3 quarters · filed 2025-02-27 | $154.91M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.16M 10-Q · filed 2024-05-02 | $3.11M derived: sum of 2 quarters · filed 2025-02-27 | $153.61M derived: sum of 3 quarters · filed 2025-02-27 | $153.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $152.45M derived: sum of 2 quarters · filed 2025-02-27 | $152.81M derived: sum of 3 quarters · filed 2025-02-27 | $153.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | $150.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $150.86M derived: sum of 2 quarters · filed 2023-11-02 | $151.05M 10-Q · filed 2023-11-02 | $153.10M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $364.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $549.00K 10-Q · filed 2023-08-03 | $2.60M derived: sum of 3 quarters · filed 2024-02-22 | $248.64M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $185.00K 10-Q · filed 2023-05-04 | $2.24M derived: sum of 2 quarters · filed 2024-02-22 | $248.28M derived: sum of 3 quarters · filed 2024-02-22 | $249.87M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $2.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $248.09M derived: sum of 2 quarters · filed 2024-02-22 | $249.69M derived: sum of 3 quarters · filed 2024-02-22 | $250.28M 10-K · filed 2024-02-22 |
| 2021-09-30 | $246.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $247.63M derived: sum of 2 quarters · filed 2022-11-03 | $248.23M 10-Q · filed 2022-11-03 | $248.50M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $2.19M 10-Q · filed 2022-08-09 | $2.46M derived: sum of 3 quarters · filed 2023-02-23 | $198.73M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $595.00K 10-Q · filed 2022-05-03 | $865.00K derived: sum of 2 quarters · filed 2023-02-23 | $197.14M derived: sum of 3 quarters · filed 2023-02-23 | $196.74M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $196.54M derived: sum of 2 quarters · filed 2023-02-23 | $196.14M derived: sum of 3 quarters · filed 2023-02-23 | $289.26M 10-K · filed 2023-02-23 |
| 2020-09-30 | $196.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $195.87M derived: sum of 2 quarters · filed 2021-11-10 | $288.99M 10-Q · filed 2021-11-10 | $310.08M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$403.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $92.72M 10-Q · filed 2021-08-06 | $113.81M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2020-03-31 | $93.12M 10-Q · filed 2021-05-06 | $114.21M derived: sum of 2 quarters · filed 2022-02-24 | ||
| 2019-12-31 | $21.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $34.91M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | $13.82M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |